Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Just a few random observations from a holder who’s stuck with Fox since 06.2015 at buys ranging from 25.5p down to 7.5p, running just a small loss. The company is good at quoting numbers of tonnes and sales in euros but, apart from financial statements, never mentions costs. So, are the already agreed orders of 3m euros for 2019 great news?sounds promising? I don’t know. So what, for sake of my argument, if t/o for 2019 totals a good increase to 5m euros. What might be the result? Maiden profit (at last) or continued losses? No clues from any RNS as to profit/loss forecasts, never has been. Annual accounts to 12.2017 gives a clue, cost of sales 800k, admin and other costs 3340k finance costs 500k total 4640k. Can only assume that, given the increased costs associated with increased production, this company has to sell well over 5m euros to get near breakeven. Mr Gilbert, what are your financial projections for 2019, breakeven would be enlightening.
A few other thoughts.
-why has lower production at Malesheva been tolerated? Poor management?
-new quarry team at Prilep massive increase in production? How long has poor production been tolerated? Poor management?
- if the various sales channels were really effective then this company would not need to be reporting virtually every sale in an RNS, what plc’s report every sale in an RNS!
So, to summarise the RNS, sales looking promising already for 2019, more equipment to produce more marble, more marble from the quarries, selling to more and more countries. 2019 is, at last, our year! Dream on. Think it’s time up for me and a switch to a company that is run properly.
Over a period of time there has been some criticism here of the BOD re their ‘silence’ / lack of news with regard to commercialisation. Approval has to be achieved of course, but I would be most confident that the board has been working extremely hard to explore all avenues and enter into discussions with key players and interested parties to enable them to decide upon the most effective way to realise the potential of Iclaprim for the company and its (us in many cases) shareholders. I would say the acceptable options are already lined up awaiting the decision, I think it’s a bit naive to think the directors have been sitting around doing nothing other than wait. Time will tell.
has been interesting and informative for a very long time, I have held Mtfb for a very long time and willl continue to work my ‘gamble’ through. I rarely bother to post. Might it be best to ignore the recent negative stuff and not be drawn into a response as this seems to fuel more ‘rubbish’? Well, one way or another, my very very long and patient wait is coming to a conclusion. Thank you to all those knowledgeable contributors, eg Ivy, over very many months.
I sat on a big loss through the debacle of last year, it’s a relief to see Redx quoted again but the SP will have to double to get me to break even. That’s after buying more upon relisting. Drug development - notoriously difficult! That said, I have been encouraged by most of the content of RNS’s and have a renewed confidence in the management, hopefully the scientific people can develop the present pipeline, if so, company management is in good hands now. Right now - I’m confident.
I rarely post but read these boards regularly. I’ve been in Aau since 2015, topped up lots, taken some profits. It seems to me the company has very few ‘investment friends’ and whatever it achieves never makes much difference to the share price anymore. With some sadness I have decided to sell out and realise fully a nice profit as I think there are better opportunities elsewhere. Might be a mistake but the past year suggests to me that whatever this company achieves makes no difference to market sentiment. Nice profit but had enough disappointment.
Thanks for sharing that qd, I read the RNS's yesterday which further advanced my opinion that Tristel is an excellent company. I started investing at just under 70p have realised some profits but recommenced buying at these levels a while ago. Tristel is a very well run business with outstanding products and, in my view, an outstanding future. When I first started reading the investment RNS my initial reaction was why buy into a company which has little to do with Tristel's core business but reading on it is clear the investment has great potential. Tristel have a policy to return unwanted cash to shareholders by special dividend, the investment in the Israeli company is potentially a fantastic way to use surplus funds. Orbimed are leaders in their investment field, I am an investor in worldwide healthcare trust which has done fantastically well and my only regret is not investing in the Biotech trust at the same time. I strongly believe my investment in Tristel is in very safe hands.
Irrespective of trading performance which remains key, there is a massive benefit from the rate rises in US, can't remember the figures but every quarter percent rate rise gives a significant increase in interest income from the bank's own cash tied up/invested in US straight to the bottom line.
Should read ' complete the final installation and testing'
Upon first reading, like several here, I found progress disappointing, it seems to take ages to actually get work done on the processing plant and it's hard to understand why it should take so long to collect muleteer the final testing and commissioning. Anyway, I've tried to retrack through the fundamentals of this business case and concluded that a top up at the lower price is worth the risk. Been here since 25.5p but with subsequent top ups not far off level now. This needs a lot of patience I think.
Thanks Tom, I did see the presentation but watching again highlighted the significant margins which give lots of breathing space to Fox to develop sales. Whilst it's slipped from the current news flow the alliance with the Kosovan Govt, with some US support, remains very exciting, so patience on that front should yield good results.
I mentioned on 26/4 that I was writing to the company to find out f they had financial projections, it's all very well announcing sales when there is no knowledge of whether or not the sales produce a profit or loss. Projections, especially breakeven sales, are important. Anyway, to cut a long story short Fox haven't replied so we're non the wiser. Pity, it's pretty basic financial stuff.
I'm with you millionaire. I am also absolutely sure that the company will continue to innovate in this exciting niche sector. As a generalisation, musicians practice and work hard to improve, some of this improvement comes from newer, better equipment so ongoing purchases of equipment is most likely. Also, irrespective of economic conditions, musicians just keep on making music! As an aside, the Investorrs Chronicle reiterated its 'buy' recommendation yesterday following the results. A great company
I am an avid reader of BB's for shares I hold or am interested in. It amazes me that there are no posts on here. Focusrite is an excellent business, a global leader in it's niche market and constantly developing new and advanced products for a market which will just keep on playing. Very profitable and financially in excellent health. What's more, the company delivers what it says it will. Really pleased to have purchased a good while back and will remain a long term holder.
I have held Fox for a good while and intend to stay long term all being well. Think future looks promising, I re BB's but rarely comment. The point was want to make, and I have written to the Co, is that sales are critical but in isolation can paint a false picture. Two examples, sales projected at 4.4m if cost of sales and overheads total say 2m then we are about to make a maiden trading profit. However if that figure is 6m then we trade at further losses. So Fox, what is the projection for break even, expected cost of sales, overheads? These projections would be informative to shareholders and the wider investment community. Also one more point. The factory us completed and capable of production through to finished product ready for sale/installation. The two orders from India and Turkey are for blocks so we are presumably not cutting and finishing which is the higher profit work. It's good to see that Fox is positioning itself as a supplier of high quality marble as there are lots of marble producers. Longer term, yes longer, the collaboration with the Kosovan Govt with potential US support may develop to the further benefit of the company. I'd sort of classify this as a weak speculative buy which, with some financial forecasts, might change to hold through to strong buy proving it's what we don't know that's so important. I am hopefully optimistic for Fox.
I've been a holder for a long time now and have followed progress very closely and also regularly read this and many other bulletin boards. I've seen this company move from explorer to producer and along the way significantly increase potential gold resources through some excellent geological work. Yes, there have been some delays, that's life, but Ariana is/was a small 'poor' company but has got there by some innovative ways of financing/building/ developing - this is massively to the credit of Kerim and his team. Quite simply, the progress has not been reflected in the share price - limited investors and a company too small maybe for institutional investors to risk. Operating in Turkey has some impact. So, in my view, having followed every development here over the years, it's not the company (done great) it's the wider investment community's lack of interest which holds the shares back. I'm here long term, in the gold resource arena this small company has works little miracles
I notice in today's IC that john rosier in his private investors diary purchased SAT on 3/2 noting 'I am attracted by the operational gearing as it adds customers to it's network, both organically and through acquisition and by the fact that it is close to moving into profit.'